Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Treatment for Rare Cancer May Help Cushing’s Patients

The cancer medicine bexarotene may hold promise for treating Cushing’s disease, a study suggests. The study, “Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT‐20 cells,” was published in the Journal of Cellular and Molecular Medicine. Cushing’s disease is caused…

COVID-19 May Be Severe in Cushing’s Patients, Case Report Suggests

A young healthcare worker who contracted COVID-19 shortly after being diagnosed with Cushing’s disease was detailed in a case report from Japan. While the woman was successfully treated for both conditions, Cushing’s may worsen a COVID-19 infection. Prompt treatment and multidisciplinary care is required for Cushing’s patients who…

Clinical Trial Will Test Fluasterone in Cushing’s Syndrome

SteroTherapeutics and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) are teaming up to conduct a Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for fluasterone as a potential treatment for the metabolic manifestations of Cushing’s syndrome. “This…